Lennar Corporation (NYSE:LEN) reported earnings of $1.30 per share, beating the Zacks Consensus Estimate of $1.13, an EPS surprise of +15.04%. The company’s reported earnings sent the stock up as much as 3.6% but closed down over 6% on the day. Their strong report stemmed from an improving housing market that has since recovered from 2018 who felt the weight of rising interest rates and home prices. Lennar reported that home sales increased 5% to 12,729 topping the company’s previous forecasts of between 11,700-12,000.
Lennar Corporation (NYSE:LEN) shares shed -6.21% to finally closed at $48.22 in last active session.
LEN’s distance from 20 day simple moving average is -7.15% and distance from 50-Day simple moving average is -7.26%.
Analyst’s mean target price for LEN is $58.00 while analysts mean recommendation is 1.80. Stock value has moved between $37.38 – 56.07 in last one year. Stock has got OUTPERFORM rating from 7 of Thomson Reuters analysts, 3 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for LEN is $58.00 while analysts mean recommendation is 1.80.
Lennar Corporation (NYSE:LEN) yearly performance is -5.82%. Annual EPS Growth of past 5 years is 21.40%. The current share price indicates that stock is -13.54% away from its one year high and is moving 29.31% ahead of its 52-week low.
On 25 June 2018, Cisco Systems, Inc. (NASDAQ:CSCO) shares shed -1.92% and ultimately finalized to $56.08 in last traded day. Stock has got OUTPERFORM rating from 10 of Thomson Reuters analysts, 11 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for CSCO is $58.63 while analysts mean recommendation is 2.00.
At the movement Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) is under coverage by number of analysts. Buy rating has been given by 0 analysts to the company stock whereas 0 given UNDERPERFORM rating to stock and 2 given HOLD rating. The consensus recommendation by Thomson Reuters analysts is -0.12 and their mean rating for the stock is 3.00 on scale of 1-5. Analysts mean target price for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) is $1.60 while their mean recommendation is 3.00 (1=Buy, 5=sell).
If we look at stock performance in last active day trading, we see that stock has moved tanked -68.54% to end the day at $0.29. The current share price indicate that stock is -95.69% away from its one year high and is moving -57.74% ahead of its 52-week low.
